Stocks · News reference
8-K filing — BioNexus Gene Lab Corp (BGLC)
Filed: 2026-10-07 AccNo: 0001477932-26-006075 Size: 247 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab
Ruanyun Edai Technology Inc. (NASDAQ: RYET) has signed a definitive agreement to grant BioNexus Gene Lab Corp. (NASDAQ: BGLC) an exclusive 10-20 year license for its Cogni AI document-intelligence platform in Malaysian healthcare. RYET will receive 560,000 BGLC shares and a 10% royalty on qualifying technology receipts. The deal aligns with Malaysia's RM1 billion healthcare digitalization initiative, though neither company has secured government contracts yet.
Ruanyun Edai Technology Inks Agreement To Grant License To BioNexus Gene Lab For Its Cogni AI Document-Intelligence Platform For Healthcare In Malaysia